<qa>  What is the sub-study of the clinical study MO22982?This prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab Herceptin SC and IV formulations in HER2-positive EBC. This is a sub-study of the clinical study MO22982 NCT01401166PrefHer. 